权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development and fundamentals of membrane processes

膜工艺的发展和基础

基本信息

批准号：
RGPIN-2014-04038
负责人：
Moresoli, Christine
金额：
$ 1.82万
依托单位：
University of Waterloo
依托单位国家：
加拿大
项目类别：
Discovery Grants Program - Individual
财政年份：
2014
资助国家：
加拿大
起止时间：
2014-01-01 至 2015-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=566256
关键词：
Development fundamentals membrane processes

项目摘要

An increasing number of therapeutic protein candidates for cancer diagnostics and treatments have reached or are near commercialization status. The purification of these therapeutic protein products can represent up to 80% of the total manufacturing costs. Alternative purification processes are needed that can deliver high purity products at affordable costs such that these products can be made available to the entire Canadian population. The long term objective of this research program is to develop selective and cost efficient purification processes that will enable the pharmaceutical industry to offer high quality therapeutic protein products to the Canadian population. Promising purification process alternatives consist of membrane chromatography materials which offer high selectivity and throughput. These materials can respond to processing conditions. Efficient membrane chromatography purification processes will be obtained by extensive characterization of the material properties and by correlating these material properties to the specific characteristics of the therapeutic proteins. Our work will extend beyond the traditional experimental approach by incorporating novel mathematical models that will capture the dynamic nature of the materials. We will also employ sophisticated material characterization techniques to obtain microscopic and transient characteristics of the purification process. Practical implementation and testing of the alternative purification processes will be obtained with promising therapeutic protein products such as monoclonal antibody.

越来越多的用于癌症诊断和治疗的治疗性蛋白候选物已经达到或接近商业化状态。这些治疗性蛋白质产品的纯化可占总制造成本的高达80%。需要替代的纯化工艺，可以以负担得起的成本提供高纯度的产品，使这些产品可以提供给整个加拿大人口。该研究计划的长期目标是开发选择性和成本效益的纯化工艺，使制药行业能够为加拿大人口提供高质量的治疗性蛋白质产品。有前途的纯化工艺替代品包括提供高选择性和通量的膜色谱材料。这些材料可以对加工条件作出反应。有效的膜色谱纯化方法将通过材料性质的广泛表征和通过将这些材料性质与治疗性蛋白质的特定特征相关联来获得。我们的工作将超越传统的实验方法，结合新的数学模型，将捕捉材料的动态性质。我们还将采用先进的材料表征技术，以获得纯化过程的微观和瞬态特性。替代纯化工艺的实际实施和测试将通过有前景的治疗性蛋白质产品（如单克隆抗体）获得。